Evidence map›Paper›PMID 25141953›Full record

ArticleClinical pharmacology and therapeutics2014

Genetic markers of cisplatin-induced hearing loss in children.

B C Carleton, C J Ross, K Pussegoda, A P Bhavsar, H Visscher, J W Lee, B Brooks, S R Rassekh, M-P P Dubé, M R Hayden

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2017
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

B C Carleton1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Division of Translational Therapeutics, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.
C J Ross1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Division of Translational Therapeutics, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [4] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
K PussegodaChild and Family Research Institute, Vancouver, British Columbia, Canada.
A P Bhavsar1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [3] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
H VisscherDepartment of Pediatrics, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands.
J W Lee1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [3] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
B BrooksAudiology and Speech Pathology Department, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
S R Rassekh1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [3] Department of Pediatrics, Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
M-P P DubéMontreal Heart Institute Research Centre and Université de Montreal, Montreal, QC, Canada.
M R HaydenCentre for Molecular Medicine and Therapeutics, Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

This journal recently published a Commentary by Ratain and colleagues at the University of Chicago that criticizes our work on cisplatin-induced hearing loss in children. It is unfortunate that neither the authors nor the editors of Clinical Pharmacology & Therapeutics corresponded with us to provide an earlier opportunity to address these questions. Here we correct the authors' inaccuracies and provide additional analyses that further strengthen our published findings.

Indexed as

Genetic VariationAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsCatechol O-MethyltransferaseCisplatinFemaleHearing LossHumansMaleMethyltransferasesAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsCatechol O-MethyltransferaseCisplatinMethyltransferases

Identifiers

PMID25141953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.